【24h】

New sepsis biomarkers

机译:新败血症生物标志物

获取原文
获取原文并翻译 | 示例
       

摘要

Sepsis remains a leading cause of death in the intensive care units and in all age groups worldwide. Early recognition and diagnosis are key to achieving improved outcomes. Therefore, novel biomarkers that might better inform clinicians treating such patients are surely needed. The main attributes of successful biomarkers would be high sensitivity, specificity, possibility of bedside monitoring and financial accessibility. A panel of sepsis biomarkers along with currently used laboratory tests will facilitate earlier diagnosis, timely treatment and improved outcome may be more effective than single biomarkers. In this review, we summarize the most recent advances on sepsis biomarkers evaluated in clinical and experimental studies.
机译:脓毒症仍然是重症监护病房和全世界所有年龄段的主要死亡原因。早期识别和诊断是实现改善预后的关键。因此,肯定需要可以更好地指导临床医生治疗此类患者的新型生物标志物。成功的生物标志物的主要特征是高度的敏感性,特异性,床旁监测的可能性和财务上的可及性。脓毒症生物标志物以及当前使用的实验室测试将有助于早期诊断,及时治疗和改善结果,比单一生物标志物更有效。在这篇综述中,我们总结了在临床和实验研究中评估的脓毒症生物标志物的最新进展。

著录项

  • 来源
    《亚太热带生物医学杂志(英文版)》 |2016年第6期|516-519|共4页
  • 作者单位

    Telematic University San Raffaele Rome, Via di Val Cannuta, 00167, Rome, Italy;

    Clinical Microbiology and Virology, Polyclinic Tor Vergata Foundation, Viale 0xford 81, 00133, Rome, Italy;

    Laboratory of Molecular Virology, Polyclinic Tor Vergata Foundation, Viale 0xford 81, 00133, Rome, Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:58:08
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号